SPRB (Spruce Biosciences) Tax Provision : $0.00 Mil (TTM As of Sep. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Spruce Biosciences Tax Provision?

Spruce Biosciences's tax provision for the three months ended in Sep. 2024 was $0.00 Mil. Its tax provision for the trailing twelve months (TTM) ended in Sep. 2024 was $0.00 Mil.

Spruce Biosciences Tax Provision Historical Data

The historical data trend for Spruce Biosciences's Tax Provision can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Spruce Biosciences Tax Provision Chart

Spruce Biosciences Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Tax Provision

Get a 7-Day Free Trial

Spruce Biosciences Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Tax Provision	Get a 7-Day Free Trial															-	-	-	-	-

Spruce Biosciences Tax Provision Calculation

Tax to be paid.

Tax Provision for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Spruce Biosciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Spruce Biosciences Inc (NAS:SPRB) » Definitions » Tax Provision

Comparable Companies

Traded in Other Exchanges

N/A

Address

611 Gateway Boulevard, Suite 740, South San Francisco, CA, USA, 94080

Website

https://www.sprucebiosciences.com

Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with unmet medical needs. The company is initially developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy to offer markedly improved disease control and reduce steroid burden for patients suffering from classic congenital adrenal hyperplasia (CAH).

Executives

Novo Holdings A/s	10 percent owner	TUBORG HAVNEVEJ 19, HELLERUP G7 2900
Percival Barretto-ko	director	611 GATEWAY BOULEVARD, SUITE 740, SOUTH SAN FRANCISCO CA 94080
Niall O'donnell	director	C/O RIVERVEST VENTURE PARTNERS, 101 SOUTH HANLEY RD., STE 1850, ST. LOUIS MO 63105
Charlton Ralph William Iii	officer: Chief Medical Officer	2001 JUNIPERO SERRA BOULEVARD, SUITE 640, DALY CITY CA 94104
Javier B. Szwarcberg	director, officer: Chief Executive Officer	2001 JUNIPERO SERRA BOULEVARD, SUITE 640, DALY CITY CA 94014
Kirk Ways	director	C/O 2001 JUNIPERO SERRA BOULEVARD, SUITE 540, DALY CITY CA 94014
Camilla V Simpson	director	20 ELAINE AVE., MILL VALLEY CA 94941
Jonas Hansson	director	18 AVENUE D'OUCHY, LAUSANNE V8 CH-1006
Bali Muralidhar	director	C/O EXICURE, INC., 8045 LAMON AVENUE, SUITE 410, SKOKIE IL 60077
Healthcap Viii, L.p.	10 percent owner	18 AVENUE D'OUCHY, C/O HEALTHCAP VIII GP SA, CH 1006 LAUSANNE V8 1006
Rivervest Venture Fund Iii (ohio), L.p.	10 percent owner	11000 CEDAR AVENUE, SUITE 100, CLEVELAND OH 44106-3502
Moghrabi Dina Chaya	director	22 GLEDHOW GARDENS, FLAT 2, LONDON X0 SW5 0AZ
Omega Fund Vi Gp Manager, Ltd.	10 percent owner	888 BOYLSTON STREET, SUITE 1111, BOSTON MA 02199
Omega Fund Vi Gp, L.p.	10 percent owner	888 BOYLSTON STREET, SUITE 1111, BOSTON MA 02199
Richard King	director, officer: Chief Executive Officer	C/O KOS PHARMACEUTICALS INC, 1001 BRICKELL AVE 25TH FL, MIAMI FL 33131